About GeneDx Holdings Corp.
http://www.genedx.comGeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.
CEO
Katherine A. Stueland
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-04 | Reverse | 1:33 |
ETFs Holding This Stock
Summary
Showing Top 3 of 134
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
BTIG
Buy
Guggenheim
Buy
Jefferies
Buy
TD Securities
Buy
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
CORVEX MANAGEMENT LP
Shares:3.06M
Value:$319.81M
CASDIN CAPITAL, LLC
Shares:3.01M
Value:$314.43M
BLACKROCK, INC.
Shares:1.53M
Value:$159.88M
Summary
Showing Top 3 of 277
About GeneDx Holdings Corp.
http://www.genedx.comGeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $116.74M ▲ | $87.78M ▲ | $-7.63M ▼ | -6.54% ▼ | $-0.27 ▼ | $-352K ▼ |
| Q2-2025 | $102.69M ▲ | $61.94M ▼ | $10.81M ▲ | 10.53% ▲ | $0.38 ▲ | $17.57M ▲ |
| Q1-2025 | $87.11M ▼ | $63.03M ▲ | $-6.53M ▼ | -7.49% ▼ | $-0.23 ▼ | $236K ▼ |
| Q4-2024 | $95.64M ▲ | $57.4M ▲ | $5.44M ▲ | 5.69% ▲ | $0.2 ▲ | $14.36M ▲ |
| Q3-2024 | $76.87M | $55.61M | $-8.31M | -10.81% | $-0.31 | $-1.85M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $155.08M ▲ | $493.9M ▲ | $201.64M ▲ | $292.26M ▲ |
| Q2-2025 | $134.56M ▼ | $463.86M ▲ | $186.73M ▼ | $277.13M ▲ |
| Q1-2025 | $159.16M ▲ | $446.43M ▲ | $189.03M ▲ | $257.4M ▲ |
| Q4-2024 | $141.19M ▲ | $419.38M ▲ | $174.13M ▼ | $245.25M ▲ |
| Q3-2024 | $116.46M | $408.84M | $204.34M | $204.5M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.63M ▼ | $15.77M ▲ | $-4.69M ▲ | $10.77M ▲ | $21.85M ▲ | $9.6M ▲ |
| Q2-2025 | $10.81M ▲ | $10.42M ▲ | $-36.35M ▼ | $346K ▼ | $-25.58M ▼ | $8.05M ▲ |
| Q1-2025 | $-6.53M ▼ | $10.18M ▲ | $-9.41M ▼ | $13.72M ▼ | $14.49M ▼ | $4.05M ▲ |
| Q4-2024 | $5.44M ▲ | $-3.18M ▲ | $-519K ▲ | $31.02M ▲ | $27.32M ▲ | $-6.23M ▼ |
| Q3-2024 | $-8.31M | $-4.39M | $-7.75M | $13.97M | $1.82M | $-5.04M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Diagnostic Test | $160.00M ▲ | $90.00M ▼ | $100.00M ▲ | $110.00M ▲ |
 Diagnostic Test Institutional Customers | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Diagnostic Test Self Pay | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Diagnostic Test Third Party Insurance | $120.00M ▲ | $70.00M ▼ | $80.00M ▲ | $100.00M ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Katherine A. Stueland
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-04 | Reverse | 1:33 |
ETFs Holding This Stock
Summary
Showing Top 3 of 134
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
BTIG
Buy
Guggenheim
Buy
Jefferies
Buy
TD Securities
Buy
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
CORVEX MANAGEMENT LP
Shares:3.06M
Value:$319.81M
CASDIN CAPITAL, LLC
Shares:3.01M
Value:$314.43M
BLACKROCK, INC.
Shares:1.53M
Value:$159.88M
Summary
Showing Top 3 of 277